PDCD1 and neoplasm: Similarly, the identification that tumour cells overexpress immune checkpoint molecules, such as PD-L-1, on their surface in order to deactivate T cells and evade immunogenic cell death, has led to the implementation ofanti-PD-1 and anti-PD-L-1 immune checkpoint inhibitor therapies that are aimed at preventing tumour cell evasion by interfering with T cell suppression signals [110].